HUP0104715A2 - Véredény szerek mágneses magrezonancia diagnosztikához - Google Patents

Véredény szerek mágneses magrezonancia diagnosztikához

Info

Publication number
HUP0104715A2
HUP0104715A2 HU0104715A HUP0104715A HUP0104715A2 HU P0104715 A2 HUP0104715 A2 HU P0104715A2 HU 0104715 A HU0104715 A HU 0104715A HU P0104715 A HUP0104715 A HU P0104715A HU P0104715 A2 HUP0104715 A2 HU P0104715A2
Authority
HU
Hungary
Prior art keywords
acid
formula
magnetic resonance
nuclear magnetic
calcium
Prior art date
Application number
HU0104715A
Other languages
English (en)
Inventor
Pier Lucio Anelli
Marino Brocchetta
Omella Gazzotti
Christoph Haen
Luciano Lattuada
Giovanna Lux
Giuseppe Manfredi
Pierfrancesco Morosini
Daniela Palano
Michele Serleti
Fulvio Uggeri
Massimo Visigalli
Original Assignee
Bracco Imaging S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bracco Imaging S.P.A. filed Critical Bracco Imaging S.P.A.
Publication of HUP0104715A2 publication Critical patent/HUP0104715A2/hu
Publication of HUP0104715A3 publication Critical patent/HUP0104715A3/hu
Publication of HU228048B1 publication Critical patent/HU228048B1/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/902Specified use of nanostructure
    • Y10S977/904Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/927Diagnostic contrast agent
    • Y10S977/928X-ray agent
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/902Specified use of nanostructure
    • Y10S977/904Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/927Diagnostic contrast agent
    • Y10S977/929Ultrasound contrast agent
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/902Specified use of nanostructure
    • Y10S977/904Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/927Diagnostic contrast agent
    • Y10S977/93MRI contrast agent

Abstract

A tal lm ny t rgya az (I) ltal nos képletű vegyületek param gneses 2-3vegyértékű féminokkal, ezen belül Fe(2+), Fe(Cu(2+), Cr(3+), Gd(3+),Eu(3+), Dy(3+), Yb(3+) vagy Mn(2+) ionokkal képzett komplexeinek, tovbb azok fiziológiailag kompatibilis szerves b zisokkal, ezen belülprimer, szekunder, tercier aminokkal vagy b zikus aminosavakkal vagyolyan szervetlen b zisokkal képzett sóinak, amelyek kationja n trium,k lium, magnézium, kalcium vagy azok elegyei alkalmaz sa az emberi ésllati test vérkeringési rendszerének m gneses magrezonanciasegítségével t"rténő kép megjelenítésére alkalmas diagnosztikumkészítmények elő llít s ra. Az (I) ltal nos képletben X jelentésepoliamino-polikarbonsav ligandum és annak sz rmazékai, ezen belülEDTA, DTPA, DOTA, DOsA, BOPTA; Y epesav-sz rmazék, ezen belülkolinsav-, kenodezoxi-kolinsav-, dezoxi-kolinsav-, urzodezoxi-kolinsav- vagy lito-kolinsav-sz rmazék mind az eredeti form j ban,mind reaktív csoportként hidroxilcsoportot tartalmazó pozíciókbanfunkciós csoporttal ell tva; L b rmely pozícióban X-hez és a 3., 7. és12. pozíciókban Y-hoz kapcsolódó l nc. A tal lm ny t rgy t képezik tovbb az (I) ltal nos képletű, új vegyületek és az ezeket tartalmazódiagnosztikum készítmények. Ó
HU0104715A 1998-12-23 1999-12-16 Blood pool agents for nuclear magnetic resonance diagnostics HU228048B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT1998MI002802A IT1304501B1 (it) 1998-12-23 1998-12-23 Uso di derivati di acidi biliari coniugati con complessi metallicicome "blood pool agents" per l'indagine diagnostica tramite risonanza
PCT/EP1999/010002 WO2000038738A1 (en) 1998-12-23 1999-12-16 Blood pool agents for nuclear magnetic resonance diagnostics

Publications (3)

Publication Number Publication Date
HUP0104715A2 true HUP0104715A2 (hu) 2002-04-29
HUP0104715A3 HUP0104715A3 (en) 2005-11-28
HU228048B1 HU228048B1 (en) 2012-09-28

Family

ID=11381326

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0104715A HU228048B1 (en) 1998-12-23 1999-12-16 Blood pool agents for nuclear magnetic resonance diagnostics

Country Status (20)

Country Link
US (1) US6461588B1 (hu)
EP (2) EP1140209B1 (hu)
JP (1) JP4733271B2 (hu)
KR (1) KR100736298B1 (hu)
CN (2) CN1263515C (hu)
AT (1) ATE405296T1 (hu)
AU (1) AU773876B2 (hu)
CA (1) CA2355888C (hu)
CZ (1) CZ302195B6 (hu)
DE (1) DE69939398D1 (hu)
HK (1) HK1042432B (hu)
HU (1) HU228048B1 (hu)
IL (2) IL143730A0 (hu)
IT (1) IT1304501B1 (hu)
MX (1) MXPA01006344A (hu)
NO (1) NO322551B1 (hu)
PL (1) PL196474B1 (hu)
RU (2) RU2250765C2 (hu)
WO (1) WO2000038738A1 (hu)
ZA (1) ZA200104820B (hu)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW319763B (hu) * 1995-02-01 1997-11-11 Epix Medical Inc
NZ503402A (en) 1997-10-02 2002-03-01 Epix Medical Inc Contrast-enhanced diagnostic imaging method for monitoring interventional therapies
IT1317862B1 (it) * 2000-02-29 2003-07-15 Bracco Spa Coniugati di acidi biliari con chelati complessi di ioni metallici eloro uso.
IT1318485B1 (it) * 2000-04-21 2003-08-25 Bracco Spa Uso di derivati di acidi biliari coniugati con complessi di ionimetallici nella visualizzazione diagnostica di sistemi microvascolari
AU2002230398A1 (en) * 2000-10-06 2002-04-29 Xenoport, Inc. Bile-acid conjugates for providing sustained systemic concentrations of drugs
EP1229041A1 (en) * 2001-02-05 2002-08-07 Bracco Imaging S.p.A. A process for the preparation of 3-Glutamido bile ester derivatives using N-tBoc methyl pyroglutamate
US7053076B2 (en) 2001-08-29 2006-05-30 Xenoport, Inc. Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
EP1302465A1 (en) 2001-10-11 2003-04-16 BRACCO IMAGING S.p.A. Enhanced substrate imaging by reversible binding to a paramagnetic complex
US8420050B2 (en) * 2003-01-13 2013-04-16 Bracco Imaging S.P.A. Gastrin releasing peptide compounds
US7850947B2 (en) 2003-01-13 2010-12-14 Bracco Imaging S.P.A. Gastrin releasing peptide compounds
US7611692B2 (en) * 2003-01-13 2009-11-03 Bracco Imaging S.P.A. Gastrin releasing peptide compounds
ATE435035T1 (de) * 2003-01-13 2009-07-15 Bracco Imaging Spa Verbesserte linker für radiopharmazeutische verbindungen
US7226577B2 (en) * 2003-01-13 2007-06-05 Bracco Imaging, S. P. A. Gastrin releasing peptide compounds
US7922998B2 (en) 2003-01-13 2011-04-12 Bracco Imaging S.P.A. Gastrin releasing peptide compounds
RU2006126637A (ru) * 2003-12-24 2008-01-27 Бракко Имэджинг С.П.А. (It) Улучшенные производные пептида, высвобождающего гастрит
US8529872B2 (en) 2007-07-11 2013-09-10 Board Of Regents, The University Of Texas System Seeds and markers for use in imaging
CN101845112B (zh) * 2010-06-02 2011-09-14 华东理工大学 一种基于高分子纳米粒子的高灵敏性核磁共振成像造影剂的制备方法
EP2665493B1 (en) 2011-01-20 2018-03-21 Board Of Regents, The University Of Texas System Mri markers, delivery and extraction systems, and methods of manufacture and use thereof
US9952300B2 (en) 2012-03-05 2018-04-24 Bracco Imaging S.P.A. Dynamic contrast enhanced MRI method and agents for the assessment of the macromolecular transport within pathologic tissues
CN102766188B (zh) * 2012-07-24 2016-01-13 上海交通大学 胆固醇衍生物、螯合物、重组高密度脂蛋白及其用途
GB201421163D0 (en) * 2014-11-28 2015-01-14 Ge Healthcare As Formulations of metal complexes
KR20200004861A (ko) 2017-05-05 2020-01-14 퓨전 파마슈티칼즈 인크. Igf-1r 모노클로날 항체 및 그의 용도
EA201992595A1 (ru) 2017-05-05 2020-04-21 Фьюжн Фармасьютикалс Инк. Усиление фармакокинетики бифункциональных хелатов и их применения
US10093741B1 (en) 2017-05-05 2018-10-09 Fusion Pharmaceuticals Inc. IGF-1R monoclonal antibodies and uses thereof
JP7463006B2 (ja) * 2018-05-30 2024-04-08 トランスレイト バイオ, インコーポレイテッド ステロイド性部分を含むカチオン性脂質

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1213029B (it) * 1986-01-30 1989-12-07 Bracco Ind Chimica Spa Chelati di ioni metallici paramagnetici.
US5227474A (en) * 1987-02-13 1993-07-13 Abbott Laboratories Bifunctional chelating agents
US5057302A (en) * 1987-02-13 1991-10-15 Abbott Laboratories Bifunctional chelating agents
DE3930696A1 (de) * 1989-09-14 1991-03-28 Hoechst Ag Gallensaeurederivate, verfahren zu ihrer herstellung, verwendung als arzneimittel
NO940115D0 (no) * 1994-01-13 1994-01-13 Nycomed Imaging As Kontrastmidler for roentgen- og magnettomografisk avbildning
WO1995028967A1 (en) * 1994-04-20 1995-11-02 Nycomed Salutar Inc Contrast agents
IT1269839B (it) * 1994-05-26 1997-04-15 Bracco Spa Coniugati di acidi biliari, loro derivati con complessi metallici e relativi usi
JPH11116542A (ja) * 1997-10-06 1999-04-27 Sogo Pharmaceut Co Ltd γ−グルタミン酸アミド類の製造法

Also Published As

Publication number Publication date
NO20013154D0 (no) 2001-06-22
JP2002533420A (ja) 2002-10-08
EP1935435B1 (en) 2017-09-06
CN1854122A (zh) 2006-11-01
IT1304501B1 (it) 2001-03-19
EP1140209B1 (en) 2008-08-20
JP4733271B2 (ja) 2011-07-27
ITMI982802A1 (it) 2000-06-23
PL196474B1 (pl) 2008-01-31
CA2355888A1 (en) 2000-07-06
CZ302195B6 (cs) 2010-12-08
AU773876B2 (en) 2004-06-10
RU2395490C2 (ru) 2010-07-27
CZ20012330A3 (cs) 2002-01-16
EP1140209A1 (en) 2001-10-10
NO20013154L (no) 2001-08-23
ATE405296T1 (de) 2008-09-15
ZA200104820B (en) 2002-06-13
IL143730A (en) 2007-09-20
RU2004127136A (ru) 2006-02-27
AU1980700A (en) 2000-07-31
MXPA01006344A (es) 2002-06-04
CN100450996C (zh) 2009-01-14
WO2000038738A1 (en) 2000-07-06
IL143730A0 (en) 2002-04-21
PL349488A1 (en) 2002-07-29
KR20010099889A (ko) 2001-11-09
EP1935435A2 (en) 2008-06-25
RU2250765C2 (ru) 2005-04-27
US6461588B1 (en) 2002-10-08
KR100736298B1 (ko) 2007-07-06
HUP0104715A3 (en) 2005-11-28
HK1042432A1 (en) 2002-08-16
CN1263515C (zh) 2006-07-12
CA2355888C (en) 2009-02-24
HU228048B1 (en) 2012-09-28
DE69939398D1 (de) 2008-10-02
EP1935435A3 (en) 2009-01-21
NO322551B1 (no) 2006-10-23
CN1333695A (zh) 2002-01-30
HK1042432B (zh) 2007-01-26

Similar Documents

Publication Publication Date Title
HUP0104715A2 (hu) Véredény szerek mágneses magrezonancia diagnosztikához
DE69117973D1 (de) Molekularsieb enthaltende pharmazeutische ionen für diagnose
US5128121A (en) Mixture of a positive and negative contrast agent for magnetic resonance imaging
RU2001120351A (ru) Агенты для кровяного депо для диагностики с помощью ядерного магнитного резонанса
US5141740A (en) Complexes and compositions for magnetic resonance imaging and usage methods
EP0436579B1 (en) Chelate compositions
IL175667A (en) Imaging factor that includes a synthetic caspase-3 inhibitor marked with the neuroimaging agent, a radiopharmaceutical containing it, a kit for preparation of the preparation and a method for diagnosis based on it
IL129173A0 (en) Gas-filled microvesicles and a process for preparing an mri contrast agent containing same
ES8603757A1 (es) Procedimiento para la obtencion de un complejo lantanido de efecto modificador del contraste de una imagen medica por rmn
NO873237L (no) Fremgangsmaate ved nmr-avbilding.
ZA965101B (en) Blood-pool imaging compositions use and method
JP2003525306A5 (hu)
DE69425572T2 (de) Iodierte paramagnetische chelaten, und deren verwendung als kontrastmittel
JP2002533420A5 (hu)
WO1994001393A1 (en) Novel chelating agent, complex compound composed of said agent and metallic atom, and diagnostic agent containing said compound
US20160051706A1 (en) Process for producing a complex of a lanthanide with a macrocyclic ligand
KR970704713A (ko) 대환식 킬레이트제, 이들의 킬레이트 및 진단 분야에서의 이의 용도(Macrocyclic Chelants, Their Chelates and Uses Thereof in the Diagnostic Field)
IL108433A0 (en) Dtpa metal complex derivatives, pharmaceutical compositions containing the same, and methods for the preparation thereof
US5314680A (en) Polyazamacrocycles for magnetic resonance imaging
US5368839A (en) Insoluble salts of lanthanides for the visual display using nuclear magnetic resonance, of the gastro-intestinal tract
US6559330B1 (en) Calcium complex of [[(4r)-4-[bis{carboxy-.kappa.o)methyl]amino-.kappa.n]-6,9-bis[(carboxy.kappa.o)methyl]-1-[(4,4-diphenylcyclohexyl)oxy]-1-hydroxy-2-oxa-6,9-diaza-1-phosphaundecan-11-ylic-acid-.kappa.n6,.kappa.n9,.kappa.011]1-oxidato(6-)]-, hexahydrogen, its salts, pharmaceutical agents that contain these complexes, their use in treatment and as additives in diagnosis, as well as processes for the production of the complexes and agents
EP1210353B1 (en) Calcium complex of phosphorus containing ethylenediamine derivatives
ES2942312T3 (es) Método de hidrólisis de éster terc-butílico usado en agente de contraste de gadolinio
US20030203879A1 (en) Calcium complex of [[(4R)-4-[bis[(carboxy-.kappa.O)methyl]amino-.kappa.n]-6,9-bis[(carboxy.kappa.O)methyl]-1-[(4,4-diphenylcyclohexy)oxy]-1-hydroxy-2-oxa-6,9-diaza-1-phosphaundecan-11-ylic-acid-.kappa.N6,.Kappa.N9,.Kappa 011]1-oxidato(6-)]-, hexahydrogen, its salts, pharmaceutical agents that contain these complexes, their use in treatment and as additives in diagnosis, as well as processes for the production of the complexes and agents
IT1271043B (it) Chelati paramagnetici per diagnosi in risonanza magnetica nucleare

Legal Events

Date Code Title Description
MM4A Lapse of definitive patent protection due to non-payment of fees